Welcome to our dedicated page for Gyrodyne SEC filings (Ticker: GYRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From Flowerfield’s 63-acre entitlement push to the Cortlandt Manor medical park leases, Gyrodyne’s story is documented in its SEC filings. Investors searching “Gyrodyne insider trading Form 4 transactions” or “Gyrodyne quarterly earnings report 10-Q filing” usually want clarity on how each zoning decision, lease renewal, or rights offering impacts land value and potential liquidating distributions. Unfortunately, those answers sit in dense 8-Ks about planning board meetings or 200-page 10-Ks packed with fair-value tables—enough complexity to make even seasoned professionals ask for “Gyrodyne SEC filings explained simply.”
Stock Titan supplies that simplicity. Our AI parses every submission the moment it hits EDGAR—whether it’s a subscription-rights prospectus or “Gyrodyne Form 4 insider transactions real-time”—and turns it into short, plain-English briefs. With comprehensive coverage of all filing types, you gain instant context: “Gyrodyne earnings report filing analysis” links NOI changes to entitlement spending, while alerts surface lease expirations buried inside exhibits. The result? “Understanding Gyrodyne SEC documents with AI” becomes a workflow, not a wish.
Dig deeper when you need to. The “Gyrodyne annual report 10-K simplified” tracks parcel-level valuation swings; 10-Qs reveal entitlement costs quarter by quarter; the proxy shows “Gyrodyne proxy statement executive compensation” after the Star Equity accord; Forms 4 capture “Gyrodyne executive stock transactions Form 4.” And when a zoning approval drops, our engine tags the “Gyrodyne 8-K material events explained,” delivering real-time insights you can act on. Stop scanning PDFs—use Stock Titan to monitor cash-flow trends, compare segment yields, and make informed decisions faster.
Gyrodyne, LLC director Ronald J. Macklin filed an amended Form 4 showing an insider transaction dated 03/12/2024. The filing reports the acquisition of 8,698 common shares through exercise of rights in a rights offering at a price of $8 per share, and records 30,441 shares beneficially owned following the transaction. The amendment corrects the number of shares acquired and the number beneficially owned as noted in the filing. The document is an amended disclosure of previously reported insider activity.
Star Equity Fund and affiliated parties report beneficial ownership of 156,774 shares of Gyrodyne, LLC, representing approximately 7.13% of the outstanding common stock based on 2,199,308 shares outstanding as of August 8, 2025. The filing is Amendment No. 7 to a Schedule 13D and states the Reporting Persons filed jointly under a Joint Filing Agreement dated August 22, 2025. The group includes Star Equity Fund, Star Equity GP, Star Investment Management, Star Operating Companies, Star Value, Hudson Global, CEO Jeffrey E. Eberwein, and nominees Hannah M. Bible and Matthew R. Sullivan. The filing confirms sole voting and dispositive power over the 156,774 shares by the named reporting entities and discloses no recent transactions for most reporting persons within the past 60 days, with Star Equity Funds recent trades referenced in an attached Schedule A.
Amendment No. 2 to Schedule 13G updates the ownership disclosure for Gyrodyne, LLC. The filing reports that Neil S. Subin beneficially owns 107,188 Common Shares, representing 4.9% of the outstanding class based on 2,199,308 shares. The Amendment states Mr. Subin has ceased to be the beneficial owner of more than 5% of the Common Shares and constitutes an exit filing. The filing also notes Mr. Subin's roles as President and Manager of MILFAM LLC and trustee for certain Miller family trusts, which relate to his management and trustee relationships to entities holding securities.
Gyrodyne (GYRO) continues to report under the liquidation basis. As of 30 Jun 2025, net assets in liquidation rose 6.6 % to $32.6 m (vs. $30.6 m at 31 Dec 2024) driven chiefly by a $4.5 m upward revaluation of real estate, partially offset by a $2.6 m increase in estimated liquidation/operating costs. Estimated shareholder distributions improved to $14.83 per share from $13.91.
Balance sheet: Real estate held for sale increased to $54.9 m (+9 %), cash slipped to $5.5 m (-7 %). Total liabilities edged up to $27.9 m, with loans outstanding at $11.0 m; all debt covenants remain compliant.
Strategy & milestones: Management still targets full liquidation by year-end 2027. A key catalyst is the July 2025 Purchase & Sale Agreement to dispose of 49 acres at Flowerfield for $24-28.74 m, contingent on subdivision and site-plan approvals; closing could extend into 2028. Entitlement work on both Flowerfield and Cortlandt Manor continues amid pending Article 78 appeals.
Risks & liquidity: Cash on hand covers roughly 18 months of projected burn; further asset sales or financing will be required if timelines slip. Operating losses are expected until closings occur. Activist shareholder Star Equity has nominated two directors for the 2025 AGM, introducing governance uncertainty.
Gyrodyne (GYRO) 8-K: Subsidiary GSD Flowerfield LLC signed a definitive agreement (30-Jul-25) to sell an ~49-acre vacant parcel at the Flowerfield complex in St. James, NY to B2K Smithtown LLC for $24.0-$28.74 million, with the final price tied to the number of market-rate units ultimately approved.
Key deal terms: (i) $250k earnest deposit; (ii) 90-day due-diligence period permitting full refund; (iii) closing deadline on the earlier of 8 months after town site-plan approval or 60 days after waiver, with a latest estimated closing of Dec-2027 (Aug-2028 if options exercised); (iv) purchase is contingent upon subdivision and other approvals within 18 months, after which the buyer may terminate or waive.
Management extended the estimated company liquidation date to 31-Dec-2027 and projects Net Asset Value in liquidation at $32.6 million, or $14.83 per share, as of 30-Jun-25, inclusive of expected transaction proceeds and additional carrying costs.
Full agreement (Ex 10.1) and related press release (Ex 99.1) filed.
FAQ
What is the current stock price of Gyrodyne (GYRO)?
What is the market cap of Gyrodyne (GYRO)?
